No Data
Fangzheng Securities: Maintains a 'strong buy' rating on sino biopharm (01177), AnFangning approved for listing by the National Medical Products Administration.
sino biopharm's self-developed KRAS G12C inhibitor Gexolase tablets (trade name: Anfangning) have been approved for market by the National Medical Products Administration.
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
sino biopharm: The KRAS G12C inhibitor Garsorase tablets 'Garsorase' have been approved for marketing.
Sino Biopharm (01177) announced that the group's jointly developed KRAS G12C inhibitor, Garsorasib tablets (trade name: Anfangning), has received marketing approval from the China National Medical Products Administration for the treatment of adult patients with late-stage non-small cell lung cancer (NSCLC) with KRAS G12C mutations who have received at least one systemic treatment. This approval is primarily based on a multicenter, single-arm, open-label pivotal Phase II study conducted in patients with locally advanced or metastatic NSCLC who are KRAS G12C mutation-positive.
Sino Biopharm's Garsorasib Gains Approval in China
sino biopharm (01177.HK): KRAS G12C inhibitor Sotorasib tablets "GARSORASIB" approved for marketing.
On November 11, Gelonhui reported that Sino Biopharm (01177.HK) announced that the jointly developed KRAS G12C inhibitor Garsorasib tablets 'Garsorasib' (trade name: Anfaining) has received market approval from the China National Medical Products Administration for the treatment of advanced non-small cell lung cancer (NSCLC) adult patients with at least one prior systemic treatment of KRAS G12C mutant.
No Data
No Data
